

Carlisle

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	4.6	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	29	19.0	152.8	(102.3-219.5)	Female	1	1.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	5	2.3	216.8	(69.9-505.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	7.3	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
Female	4	5.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	1.4	nc	(nc-nc)	Male	20	21.8	91.9	(56.1-142.0)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.4	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	2.4	nc	(nc-nc)	Female	2	4.0	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.9	nc	(nc-nc)	Male	51	68.7	74.2	(55.3-97.6)
Female	0	0.2	nc	(nc-nc)	Female	52	56.0	92.9	(69.4-121.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.6	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	1	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	4	9.2	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	3	7.0	nc	(nc-nc)	<u>All Sites / Types</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

60
Carver

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	13.8	101.8	(55.6-170.8)	Male	7	7.3	95.5	(38.3-196.8)
Female	5	4.5	110.0	(35.4-256.6)	Female	5	5.7	88.1	(28.4-205.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.5	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	6	6.9	87.6	(32.0-190.6)
Female	38	45.8	83.0	(58.7-114.0)	Female	3	5.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.0	nc	(nc-nc)	Male	7	4.8	145.0	(58.1-298.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	19	20.3	93.6	(56.3-146.2)	Female	6	4.9	121.7	(44.4-264.8)
Female	21	17.8	117.7	(72.8-179.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	3.8	nc	(nc-nc)
Male	6	3.4	176.6	(64.5-384.5)	Female	7	3.8	182.1	(73.0-375.3)
Female	1	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	54	50.7	106.5	(80.0-138.9)
Male	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.8	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	1.9	nc	(nc-nc)
Male	10	5.5	181.6	(86.9-333.9)	<u>Testis</u>				
Female	7	3.3	209.6	(84.0-432.0)	Male	2	1.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	2.2	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	7	4.7	147.6	(59.1-304.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	4.3	164.2	(65.8-338.4)	Female	6	9.4	64.0	(23.4-139.3)
Female	3	3.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	193	176.0	109.7	(94.7-126.3)
Male	2	2.7	nc	(nc-nc)	Female	158	155.7	101.5	(86.3-118.6)
Female	1	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	28	25.2	111.1	(73.8-160.5)					
Female	23	22.0	104.6	(66.3-156.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;

- nc = The SIR and 95% CI were not calculated when Obs < 5;

61

Charlemont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.4	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	10	5.4	185.7	(88.9-341.5)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	2.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Female</u>				
Male	2	0.5	nc	(nc-nc)	Male	12	19.7	60.9	(31.5-106.5)
Female	0	0.4	nc	(nc-nc)	Female	17	17.5	97.0	(56.5-155.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Male</u>				
Male	0	0.3	nc	(nc-nc)	<u>Female</u>				
Female	0	0.1	nc	(nc-nc)	<u>Male</u>				
<u>Lung and Bronchus</u>					<u>Female</u>				
Male	3	2.7	nc	(nc-nc)	<u>Male</u>				
Female	0	2.3	nc	(nc-nc)	<u>Female</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

62

Charlton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	8.8	nc	(nc-nc)	Male	2	5.8	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	3	5.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	2.2	276.3	(100.9-601.3)	Male	1	1.4	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.2	97.0	(31.3-226.3)
Female	40	37.0	108.2	(77.3-147.4)	Female	6	4.2	142.9	(52.2-311.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.0	nc	(nc-nc)	Male	5	4.0	125.3	(40.4-292.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	16	13.7	117.2	(66.9-190.3)	Female	4	3.9	nc	(nc-nc)
Female	15	12.3	121.7	(68.1-200.8)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	2.4	nc	(nc-nc)	Male	36	35.8	100.5	(70.4-139.2)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	1.0	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	4.2	nc	(nc-nc)	Female	11	7.2	152.1	(75.8-272.2)
Female	3	2.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.6	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	4.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.2	nc	(nc-nc)	Female	11	7.2	152.1	(75.8-272.2)
Female	2	2.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.1	nc	(nc-nc)	Female	11	7.2	152.1	(75.8-272.2)
Female	0	0.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	18	16.4	109.5	(64.9-173.1)	Male	120	124.9	96.1	(79.6-114.9)
Female	19	14.1	135.2	(81.4-211.2)	Female	128	117.7	108.8	(90.7-129.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

63

Chatham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	25	16.8	148.7	(96.2-219.5)	Male	11	7.5	147.5	(73.6-264.0)
Female	10	5.9	170.0	(81.4-312.7)	Female	9	5.3	170.0	(77.6-322.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.2	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.5	nc	(nc-nc)	Male	5	7.3	68.9	(22.2-160.7)
Female	74	46.4	159.4	(125.2-200.2)	Female	6	6.9	86.7	(31.7-188.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.6	nc	(nc-nc)	Male	4	4.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	25	23.9	104.8	(67.8-154.7)	Female	10	5.2	191.8	(91.8-352.8)
Female	22	23.5	93.5	(58.6-141.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	4.5	111.3	(35.9-259.7)
Male	6	3.8	155.9	(56.9-339.4)	Female	7	5.1	137.7	(55.2-283.7)
Female	1	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	81	58.5	138.4	(109.9-172.0)
Male	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.5	nc	(nc-nc)	Male	1	4.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	2.6	nc	(nc-nc)
Male	12	5.8	207.0	(106.8-361.6)	<u>Testis</u>				
Female	2	3.7	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	2.4	206.4	(66.5-481.8)	Male	1	1.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	3.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	4.5	nc	(nc-nc)	Female	12	9.9	121.3	(62.6-211.9)
Female	4	3.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	224	198.7	112.7	(98.4-128.5)
Male	2	2.8	nc	(nc-nc)					
Female	0	1.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	19	30.0	63.3	(38.1-98.9)					

Female 23 26.5 86.9 (55.0-130.3)

Female 209 173.8 120.3 (104.5-137.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

64

Chelmsford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	34.9	83.1	(55.6-119.4)	Male	18	20.5	87.7	(52.0-138.6)
Female	15	13.7	109.3	(61.1-180.3)	Female	12	17.7	67.9	(35.1-118.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	7.1	nc	(nc-nc)	Male	4	5.4	nc	(nc-nc)
Female	2	6.1	nc	(nc-nc)	Female	1	4.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.1	nc	(nc-nc)	Male	23	18.5	124.4	(78.8-186.7)
Female	157	144.5	108.7	(92.3-127.1)	Female	20	17.8	112.7	(68.8-174.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	6.5	77.5	(25.0-180.8)	Male	10	14.2	70.2	(33.6-129.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	58	53.1	109.2	(83.0-141.2)	Female	15	15.4	97.3	(54.4-160.5)
Female	57	53.9	105.8	(80.2-137.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	10.1	79.1	(34.1-155.9)
Male	11	9.3	118.4	(59.0-211.8)	Female	6	11.5	52.1	(19.0-113.3)
Female	3	2.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	157	146.0	107.6	(91.4-125.8)
Male	1	2.8	nc	(nc-nc)	<u>Stomach</u>				
Female	4	2.3	nc	(nc-nc)	Male	5	8.9	56.1	(18.1-130.8)
<u>Kidney & Renal Pelvis</u>					Female	4	5.7	nc	(nc-nc)
Male	20	15.7	127.5	(77.8-196.9)	<u>Testis</u>				
Female	10	10.1	98.6	(47.2-181.4)	Male	6	5.0	120.0	(43.8-261.2)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	6.1	81.4	(26.2-190.1)	Male	9	4.6	197.4	(90.1-374.7)
Female	1	1.8	nc	(nc-nc)	Female	14	15.0	93.5	(51.1-156.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	13	11.4	114.5	(60.9-195.7)	Female	36	30.3	118.7	(83.1-164.3)
Female	11	9.7	113.2	(56.4-202.5)					
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	11	7.6	144.6	(72.1-258.7)					
Female	2	2.8	nc	(nc-nc)					

Lung and Bronchus

Male	67	66.8	100.3	(77.7-127.4)
Female	61	65.8	92.7	(70.9-119.1)

All Sites / Types

Male	497	481.9	103.1	(94.3-112.6)
Female	468	480.2	97.5	(88.8-106.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

65

Chelsea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	30	30.5	98.3	(66.3-140.3)	Male	6	17.7	33.9	(12.4-73.7)
Female	8	10.6	75.8	(32.6-149.4)	Female	11	14.4	76.2	(38.0-136.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	6.5	92.7	(33.8-201.7)	Male	9	4.6	195.1	(89.0-370.4)
Female	8	5.1	156.6	(67.4-308.6)	Female	1	3.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	17	16.3	104.5	(60.8-167.3)
Female	87	104.1	83.5	(66.9-103.1)	Female	17	13.9	122.2	(71.2-195.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	13	5.3	246.3	(131.0-421.2)	Male	20	11.1	180.9	(110.4-279.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	51	45.4	112.3	(83.6-147.6)	Female	10	11.4	87.5	(41.9-160.9)
Female	45	42.3	106.3	(77.5-142.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	8.5	105.6	(48.2-200.5)
Male	16	7.6	210.7	(120.3-342.2)	Female	6	9.0	66.8	(24.4-145.5)
Female	1	2.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	86	114.0	75.4	(60.3-93.1)
Male	4	3.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	2.6	nc	(nc-nc)	Male	10	7.9	127.1	(60.9-233.8)
<u>Kidney & Renal Pelvis</u>					Female	5	4.7	107.2	(34.5-250.2)
Male	20	12.7	157.9	(96.4-243.8)	<u>Testis</u>				
Female	7	7.6	92.2	(36.9-190.0)	Male	1	6.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	13	4.9	265.6	(141.3-454.3)	Male	4	4.0	nc	(nc-nc)
Female	5	1.3	391.2	(126.1-912.9)	Female	12	13.0	92.5	(47.8-161.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	10.4	76.6	(33.0-151.0)					
Female	7	8.2	85.3	(34.2-175.7)					
<u>Liver and Intrahepatic Bile Ducts</u>									

Male	12	6.1	198.0	(102.2-346.0)					
Female	4	2.2	nc	(nc-nc)	Female	21	21.1	99.6 (61.6-152.2)	
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	62	55.9	110.8	(85.0-142.1)	Male	416	404.0	103.0 (93.3-113.4)	
Female	51	48.5	105.2	(78.3-138.3)	Female	354	364.3	97.2 (87.3-107.8)	

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

66

Cheshire

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	4.4	113.9	(36.7-265.8)	Male	1	2.4	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	4	1.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	0.8	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	18	13.9	129.7	(76.8-205.0)	Female	2	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
					Female	0	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	6.6	120.8	(52.0-238.0)	Female	0	1.5	nc	(nc-nc)
Female	6	5.0	121.1	(44.2-263.6)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.1	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	4	1.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	15	17.9	84.0	(47.0-138.6)
Female	0	0.2	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	2	1.9	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	4	1.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)

Female	0	0.9	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.9	nc	(nc-nc)	Female	0	2.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male	61	58.9	103.5	(79.2-133.0)
Male	12	8.3	144.7	(74.7-252.8)	Female	56	45.4	123.2	(93.1-160.0)
Female	12	6.2	192.5	(99.3-336.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

67

Chester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.4	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	5	5.0	101.0	(32.5-235.6)	Female	1	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.2	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.7	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.1	nc	(nc-nc)	Male	3	5.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)					

Leukemia

Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)

Lung and Bronchus

Male	3	2.7	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)

Thyroid

Male	0	0.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	2	1.0	nc	(nc-nc)
--------	---	-----	----	---------

All Sites / Types

Male	13	19.4	67.1	(35.7-114.8)
Female	18	15.9	112.9	(66.9-178.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

68

Chesterfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	1	1.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	4	4.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.2	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	0	1.9	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Pancreas				
Esophagus					Male	0	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Prostate				
Hodgkin Lymphoma					Male	3	5.2	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Stomach				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Kidney & Renal Pelvis					Female	0	0.1	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Testis				
Female	0	0.3	nc	(nc-nc)					
Larynx									

Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.3	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	1	2.4	nc	(nc-nc)	Male	9	17.3	51.9	(23.7-98.6)
Female	3	1.8	nc	(nc-nc)	Female	13	14.3	91.0	(48.4-155.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

69

Chicopee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	68	68.8	98.8	(76.7-125.3)	Male	28	36.1	77.5	(51.5-112.0)
Female	33	26.8	123.0	(84.6-172.7)	Female	26	30.4	85.6	(55.9-125.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	12.1	99.0	(51.1-172.9)	Male	10	10.2	97.9	(46.8-180.0)
Female	9	10.7	84.4	(38.5-160.2)	Female	12	8.6	140.2	(72.3-244.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	2.0	nc	(nc-nc)	Male	26	33.9	76.8	(50.1-112.5)
Female	246	247.1	99.6	(87.5-112.8)	Female	26	33.7	77.1	(50.3-112.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	10.4	67.6	(27.1-139.3)	Male	25	23.9	104.7	(67.8-154.6)
Female	7	10.4	67.6	(27.1-139.3)	Female	11	12.5	88.3	(44.0-158.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	89	101.4	87.8	(70.5-108.0)	Female	27	27.1	99.6	(65.6-145.0)
Female	111	106.1	104.6	(86.0-125.9)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	20	17.0	117.8	(71.9-181.9)	Male	9	19.1	47.0	(21.4-89.2)
Female	4	5.2	nc	(nc-nc)	Female	18	22.9	78.7	(46.6-124.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	4.9	nc	(nc-nc)	Male	255	257.9	98.9	(87.1-111.8)
Female	4	4.2	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	22	27.4	80.2	(50.3-121.5)	Male	22	17.3	126.8	(79.5-192.1)

Female	16	18.7	85.7	(48.9-139.1)	Female	13	11.4	114.0	(60.6-194.9)
<u>Larynx</u>					<u>Testis</u>				
Male	8	10.9	73.4	(31.6-144.6)	Male	7	8.0	87.6	(35.1-180.5)
Female	3	3.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male	1	7.2	nc	(nc-nc)
Male	22	21.0	104.7	(65.6-158.6)	Female	17	23.7	71.8	(41.8-115.0)
Female	13	18.3	70.9	(37.7-121.3)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female	67	51.5	130.2	(100.9-165.4)
Male	14	13.2	105.9	(57.9-177.8)	<u>All Sites / Types</u>				
Female	7	5.3	132.1	(52.9-272.1)	Male	838	882.3	95.0	(88.7-101.6)
<u>Lung and Bronchus</u>					Female	852	872.4	97.7	(91.2-104.4)
Male	128	127.1	100.7	(84.0-119.8)					
Female	110	126.2	87.2	(71.6-105.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

70

Chilmark

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.5	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	3	4.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.8	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	8	5.8	137.6	(59.3-271.2)
Female	0	0.1	nc	(nc-nc)					

Kidney & Renal Pelvis

Male	2	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)

Larynx

Male	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)

Leukemia

Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)

Lung and Bronchus

Male	0	2.7	nc	(nc-nc)
Female	4	2.1	nc	(nc-nc)

Stomach

Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)

Testis

Male	0	0.1	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	0	0.1	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	0	1.0	nc	(nc-nc)
--------	---	-----	----	---------

All Sites / Types

Male	17	19.2	88.7	(51.7-142.1)
Female	10	15.1	66.1	(31.6-121.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

71

Clarksburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	4	7.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
					Female	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	3.3	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				

Male	1	0.2	nc	(nc-nc)	Male	6	9.4	64.1	(23.4-139.6)
Female	0	0.1	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	1	0.9	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	2	0.4	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	1	0.7	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.5	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	9	4.2	212.5	(96.9-403.3)	Male	28	29.8	94.0	(62.4-135.8)
Female	7	3.6	193.7	(77.6-399.2)	Female	25	25.5	98.2	(63.6-145.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

72

Clinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	14.4	90.1	(47.9-154.0)	Male	5	8.1	61.7	(19.9-143.9)
Female	5	6.0	83.3	(26.8-194.4)	Female	7	7.2	97.3	(39.0-200.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.8	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	0	2.5	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	7.5	67.0	(21.6-156.4)
Female	39	56.6	68.9	(49.0-94.1)	Female	6	7.6	78.5	(28.7-170.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	2.5	237.6	(86.8-517.3)	Male	7	5.3	131.8	(52.8-271.7)
Female	6	2.5	237.6	(86.8-517.3)	Female	2	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	24	21.5	111.6	(71.5-166.1)	Female	10	6.2	161.4	(77.3-296.9)
Female	22	24.0	91.5	(57.3-138.5)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.6	137.6	(44.3-321.1)	Male	2	4.1	nc	(nc-nc)

Female	2	1.2	nc	(nc-nc)	Female	3	5.1	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	2	1.2	nc	(nc-nc)	Male	41	55.1	74.4	(53.4-100.9)
Female	0	1.1	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	3	3.7	nc	(nc-nc)
Male	3	6.0	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
Female	6	4.2	143.0	(52.2-311.3)	Testis				
Larynx					Male	0	2.2	nc	(nc-nc)
Male	4	2.3	nc	(nc-nc)	Thyroid				
Female	1	0.7	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Leukemia					Female	4	5.9	nc	(nc-nc)
Male	2	4.6	nc	(nc-nc)	Uteri Corpus and Uterus, NOS				
Female	4	4.2	nc	(nc-nc)	Female	5	11.6	43.1	(13.9-100.6)
Liver and Intrahepatic Bile Ducts					All Sites / Types				
Male	5	2.9	172.2	(55.5-401.9)	Male	172	190.1	90.5	(77.5-105.0)
Female	0	1.2	nc	(nc-nc)	Female	158	198.7	79.5	(67.6-92.9)
Lung and Bronchus									
Male	31	26.8	115.6	(78.6-164.1)					
Female	18	27.8	64.8	(38.4-102.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

73

Cohasset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	14	8.7	160.3	(87.6-269.0)	Male	10	4.8	206.2	(98.7-379.3)
Female	3	3.2	nc	(nc-nc)	Female	14	3.9	357.3	(195.2-599.6)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	1.7	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.3	nc	(nc-nc)	Male	6	4.4	135.2	(49.4-294.3)
Female	32	32.9	97.4	(66.6-137.5)	Female	2	4.1	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	2	1.4	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Colon / Rectum					Female	1	1.6	nc	(nc-nc)
Male	16	13.2	121.6	(69.5-197.5)	Ovary				
Female	15	12.6	119.0	(66.6-196.3)	Female	6	3.5	170.5	(62.3-371.2)

Esophagus

Male	1	2.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)

Hodgkin Lymphoma

Male	0	0.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)

Kidney & Renal Pelvis

Male	6	3.8	159.6	(58.3-347.5)
Female	1	2.4	nc	(nc-nc)

Larynx

Male	0	1.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)

Leukemia

Male	4	2.7	nc	(nc-nc)
Female	0	2.2	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	1	1.8	nc	(nc-nc)
Female	3	0.6	nc	(nc-nc)

Lung and Bronchus

Male	14	16.5	85.1	(46.5-142.8)
Female	10	15.4	65.1	(31.2-119.8)

Pancreas

Male	3	2.5	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)

Prostate

Male	35	35.2	99.4	(69.2-138.2)
------	----	------	------	--------------

Stomach

Male	1	2.2	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)

Testis

Male	0	0.9	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	2	1.0	nc	(nc-nc)
Female	5	3.2	156.5	(50.4-365.2)

Uteri Corpus and Uterus, NOS

Female	7	6.8	102.2	(40.9-210.6)
--------	---	-----	-------	--------------

All Sites / Types

Male	130	116.9	111.3	(92.9-132.1)
Female	111	110.1	100.8	(82.9-121.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Colrain

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	8	6.7	118.7	(51.1-233.9)	Female	0	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
					Female	1	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				

Male	2	3.2	nc	(nc-nc)					
Female	1	2.3	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	3	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	8.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.8	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.4	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.4	nc	(nc-nc)	Male	17	28.7	59.2	(34.5-94.8)
Female	0	0.1	nc	(nc-nc)	Female	25	21.8	114.9	(74.3-169.6)
<u>Lung and Bronchus</u>									
Male	4	4.0	nc	(nc-nc)					
Female	7	2.9	239.3	(95.9-493.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

75

Concord

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	23.1	69.1	(39.5-112.3)	Male	27	12.5	215.6	(142.1-313.7)
Female	10	7.9	127.3	(61.0-234.2)	Female	22	9.1	241.8	(151.5-366.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.2	nc	(nc-nc)	Male	6	3.5	172.1	(62.9-374.7)
Female	4	3.2	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	14	11.6	121.1	(66.2-203.3)
Female	98	77.9	125.9	(102.2-153.4)	Female	14	9.8	142.3	(77.7-238.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
					Male	8	8.5	93.6	(40.3-184.5)

Female	3	3.2	nc	(nc-nc)	Female	5	3.8	132.0	(42.5-308.0)
Colon / Rectum					Ovary				
Male	24	34.4	69.8	(44.7-103.8)	Female	8	8.4	95.4	(41.1-187.9)
Female	31	31.3	99.1	(67.3-140.6)	Pancreas				
Esophagus					Male	3	6.5	nc	(nc-nc)
Male	1	5.8	nc	(nc-nc)	Female	12	6.7	179.7	(92.8-314.0)
Female	2	1.5	nc	(nc-nc)	Prostate				
Hodgkin Lymphoma					Male	100	89.9	111.2	(90.5-135.3)
Male	3	1.5	nc	(nc-nc)	Stomach				
Female	0	1.1	nc	(nc-nc)	Male	2	5.9	nc	(nc-nc)
Kidney & Renal Pelvis					Female	2	3.4	nc	(nc-nc)
Male	4	9.6	nc	(nc-nc)	Testis				
Female	11	5.6	197.0	(98.2-352.6)	Male	6	2.5	241.1	(88.0-524.7)
Larynx					Thyroid				
Male	2	3.8	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	5	7.1	70.1	(22.6-163.5)
Leukemia					Uteri Corpus and Uterus, NOS				
Male	9	7.0	127.9	(58.4-242.8)	Female	21	16.3	128.9	(79.8-197.1)
Female	4	5.4	nc	(nc-nc)	All Sites / Types				
Liver and Intrahepatic Bile Ducts					Male	270	302.4	89.3	(79.0-100.6)
Male	4	4.7	nc	(nc-nc)	Female	290	263.6	110.0	(97.7-123.4)
Female	3	1.6	nc	(nc-nc)					
Lung and Bronchus									
Male	20	43.0	46.5	(28.4-71.9)					
Female	21	36.6	57.3	(35.5-87.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

76

Conway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	0	1.8	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	8	7.3	109.2	(47.0-215.2)	Female	0	0.8	nc	(nc-nc)

Cervix Uteri

Female	1	0.3	nc	(nc-nc)
--------	---	-----	----	---------

Colon / Rectum

Male	2	2.8	nc	(nc-nc)
------	---	-----	----	---------

Female	4	2.3	nc	(nc-nc)
--------	---	-----	----	---------

Esophagus

Male	0	0.5	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.1	nc	(nc-nc)
--------	---	-----	----	---------

Hodgkin Lymphoma

Male	0	0.2	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.1	nc	(nc-nc)
--------	---	-----	----	---------

Kidney & Renal Pelvis

Male	1	0.9	nc	(nc-nc)
------	---	-----	----	---------

Female	1	0.5	nc	(nc-nc)
--------	---	-----	----	---------

Larynx

Male	1	0.3	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.1	nc	(nc-nc)
--------	---	-----	----	---------

Leukemia

Male	1	0.6	nc	(nc-nc)
------	---	-----	----	---------

Female	1	0.4	nc	(nc-nc)
--------	---	-----	----	---------

Liver and Intrahepatic Bile Ducts

Male	0	0.4	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.1	nc	(nc-nc)
--------	---	-----	----	---------

Lung and Bronchus

Male	1	3.5	nc	(nc-nc)
------	---	-----	----	---------

Female	2	2.8	nc	(nc-nc)
--------	---	-----	----	---------

Oral Cavity & Pharynx

Male	1	0.8	nc	(nc-nc)
------	---	-----	----	---------

Female	1	0.3	nc	(nc-nc)
--------	---	-----	----	---------

Ovary

Female	0	0.8	nc	(nc-nc)
--------	---	-----	----	---------

Pancreas

Male	0	0.5	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.5	nc	(nc-nc)
--------	---	-----	----	---------

Prostate

Male	11	7.8	141.3	(70.4-252.8)
------	----	-----	-------	--------------

Stomach

Male	0	0.5	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.2	nc	(nc-nc)
--------	---	-----	----	---------

Testis

Male	0	0.3	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	0	0.3	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.8	nc	(nc-nc)
--------	---	-----	----	---------

Uteri Corpus and Uterus, NOS

Female	0	1.5	nc	(nc-nc)
--------	---	-----	----	---------

All Sites / Types

Male	22	25.8	85.1	(53.3-128.9)
------	----	------	------	--------------

Female	22	22.5	97.8	(61.2-148.0)
--------	----	------	------	--------------

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

77

Cummington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				

Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	3	3.8	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.2	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<u>Ovary</u>				
Female	2	1.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	2	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.2	nc	(nc-nc)	Male	10	13.6	73.7	(35.3-135.5)
Female	0	0.1	nc	(nc-nc)	Female	15	12.3	121.9	(68.2-201.1)
<u>Lung and Bronchus</u>									
Male	3	1.9	nc	(nc-nc)					
Female	3	1.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

78

Dalton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	8.1	110.8	(50.6-210.4)	Male	13	4.4	294.6	(156.7-503.8)
Female	4	3.3	nc	(nc-nc)	Female	4	3.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.5	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)

Female	5	1.3	374.7	(120.8-874.4)	Female	1	1.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	0.2	nc	(nc-nc)	Male	6	4.1	146.7	(53.6-319.4)
Female	31	31.7	97.7	(66.4-138.7)	Female	2	4.2	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	1.3	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Colon / Rectum					Female	1	1.6	nc	(nc-nc)
Male	14	12.1	115.5	(63.1-193.9)	Ovary				
Female	20	13.3	150.9	(92.1-233.0)	Female	2	3.4	nc	(nc-nc)
Esophagus					Pancreas				
Male	2	2.1	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	1	0.6	nc	(nc-nc)	Male	34	31.6	107.6	(74.5-150.3)
Female	0	0.5	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	1	2.1	nc	(nc-nc)
Male	6	3.4	178.0	(65.0-387.4)	Female	1	1.4	nc	(nc-nc)
Female	4	2.3	nc	(nc-nc)	Testis				
Larynx					Male	3	0.9	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	Thyroid				
Female	0	0.4	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Leukemia					Female	5	3.0	167.2	(53.9-390.2)
Male	2	2.5	nc	(nc-nc)	Uteri Corpus and Uterus, NOS				
Female	2	2.3	nc	(nc-nc)	Female	4	6.6	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					All Sites / Types				
Male	2	1.6	nc	(nc-nc)	Male	120	106.6	112.6	(93.3-134.6)
Female	0	0.7	nc	(nc-nc)	Female	117	109.9	106.5	(88.1-127.6)
Lung and Bronchus									

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

79

Danvers

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	39	31.6	123.3	(87.6-168.5)	Male	21	16.9	124.1	(76.8-189.7)
Female	9	12.5	72.2	(32.9-137.0)	Female	11	14.4	76.4	(38.1-136.7)

Brain and Other Nervous System

Male	7	5.6	124.1	(49.7-255.7)
Female	8	5.0	159.3	(68.6-313.9)

Breast

Male	1	0.9	nc	(nc-nc)
Female	124	118.4	104.7	(87.1-124.8)

Cervix Uteri

Female	4	5.0	nc	(nc-nc)
--------	---	-----	----	---------

Colon / Rectum

Male	62	46.9	132.3	(101.4-169.6)
Female	53	49.6	106.8	(80.0-139.7)

Esophagus

Male	8	7.9	100.8	(43.4-198.6)
Female	3	2.4	nc	(nc-nc)

Hodgkin Lymphoma

Male	3	2.1	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)

Kidney & Renal Pelvis

Male	15	12.9	116.2	(65.0-191.6)
Female	7	8.7	80.4	(32.2-165.7)

Larynx

Male	0	5.2	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)

Leukemia

Male	15	9.6	155.9	(87.2-257.2)
Female	9	8.6	104.9	(47.9-199.2)

Liver and Intrahepatic Bile Ducts

Male	6	6.3	95.7	(34.9-208.3)
Female	1	2.5	nc	(nc-nc)

Lung and Bronchus

Male	61	58.8	103.7	(79.3-133.2)
Female	69	57.9	119.1	(92.7-150.8)

Multiple Myeloma

Male	5	4.7	105.4	(34.0-246.0)
Female	2	3.9	nc	(nc-nc)

Non-Hodgkin Lymphoma

Male	22	15.7	140.2	(87.8-212.3)
Female	16	15.6	102.3	(58.4-166.2)

Oral Cavity & Pharynx

Male	7	11.4	61.3	(24.5-126.2)
Female	9	5.9	153.2	(69.9-290.9)

Ovary

Female	18	12.9	139.7	(82.7-220.7)
--------	----	------	-------	--------------

Pancreas

Male	11	8.9	124.1	(61.8-222.0)
Female	9	10.6	84.7	(38.7-160.8)

Prostate

Male	117	122.4	95.6	(79.0-114.5)
------	-----	-------	------	--------------

Stomach

Male	7	8.0	87.7	(35.1-180.7)
Female	4	5.4	nc	(nc-nc)

Testis

Male	6	3.5	172.5	(63.0-375.4)
------	---	-----	-------	--------------

Thyroid

Male	3	3.4	nc	(nc-nc)
Female	8	11.4	70.1	(30.2-138.2)

Uteri Corpus and Uterus, NOS

Female	18	24.5	73.3	(43.4-115.9)
--------	----	------	------	--------------

All Sites / Types

Male	454	411.7	110.3	(100.4-120.9)
Female	431	411.0	104.9	(95.2-115.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dartmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>				<u>Melanoma of Skin</u>			

Male	41	36.5	112.3	(80.6-152.3)	Male	15	20.0	75.0	(42.0-123.7)
Female	20	13.5	148.1	(90.4-228.7)	Female	21	16.0	131.6	(81.4-201.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	6.8	118.1	(50.9-232.7)	Male	10	5.5	181.9	(87.1-334.5)
Female	5	5.5	90.4	(29.1-211.1)	Female	9	4.3	208.7	(95.3-396.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.1	nc	(nc-nc)	Male	16	18.5	86.4	(49.4-140.4)
Female	129	130.1	99.1	(82.8-117.8)	Female	17	17.1	99.2	(57.8-158.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	5.5	127.0	(50.9-261.7)	Male	17	13.5	126.3	(73.5-202.3)
<u>Colon / Rectum</u>					Female	4	6.5	nc	(nc-nc)
Male	76	54.4	139.7	(110.0-174.8)	<u>Ovary</u>				
Female	46	53.7	85.7	(62.7-114.3)	Female	11	14.2	77.5	(38.6-138.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	9.2	54.3	(17.5-126.7)	Male	14	10.3	136.0	(74.3-228.2)
Female	1	2.6	nc	(nc-nc)	Female	14	11.5	121.6	(66.4-204.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.9	nc	(nc-nc)	Male	170	140.7	120.9	(103.4-140.5)
Female	3	2.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	12	9.3	129.4	(66.8-226.1)
Male	27	15.0	179.4	(118.2-261.1)	Female	11	5.8	190.4	(94.9-340.7)
Female	9	9.5	94.3	(43.0-179.0)	<u>Testis</u>				
<u>Larynx</u>					Male	2	4.8	nc	(nc-nc)
Male	6	6.0	100.6	(36.7-218.9)	<u>Thyroid</u>				
Female	2	1.6	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
<u>Leukemia</u>					Female	13	12.8	101.5	(54.0-173.5)
Male	15	11.4	131.7	(73.7-217.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	9.3	64.3	(23.5-139.9)	Female	36	27.0	133.1	(93.2-184.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	7.3	81.8	(29.9-178.0)	Male	530	478.8	110.7	(101.5-120.5)
Female	2	2.7	nc	(nc-nc)	Female	461	450.1	102.4	(93.3-112.2)
<u>Lung and Bronchus</u>									
Male	62	67.7	91.6	(70.2-117.5)					
Female	60	63.4	94.6	(72.2-121.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	31	29.8	103.9	(70.6-147.4)	Male	15	16.0	94.0	(52.6-155.1)
Female	11	11.0	100.0	(49.8-178.9)	Female	13	12.9	100.7	(53.5-172.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.3	112.7	(41.2-245.3)	Male	7	4.5	157.2	(63.0-323.9)
Female	3	4.5	nc	(nc-nc)	Female	5	3.5	143.3	(46.2-334.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	18	14.8	121.5	(72.0-192.1)
Female	136	105.8	128.6	(107.9-152.1)	Female	12	13.8	86.7	(44.8-151.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.5	nc	(nc-nc)	Male	15	10.6	141.5	(79.2-233.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	42	44.1	95.3	(68.7-128.8)	Female	15	11.5	130.8	(73.2-215.8)
Female	48	43.2	111.2	(82.0-147.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	8.3	84.0	(33.6-173.0)
Male	7	7.4	94.1	(37.7-194.0)	Female	8	9.3	86.0	(37.0-169.4)
Female	2	2.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	137	113.7	120.5	(101.2-142.5)
Male	2	2.1	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.7	nc	(nc-nc)	Male	9	7.5	119.5	(54.5-226.9)
<u>Kidney & Renal Pelvis</u>					Female	3	4.6	nc	(nc-nc)
Male	18	12.1	148.9	(88.2-235.4)	<u>Testis</u>				
Female	9	7.8	115.8	(52.8-219.8)	Male	5	3.5	141.2	(45.5-329.6)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	4.8	104.1	(33.5-242.8)	Male	7	3.2	216.4	(86.7-445.8)
Female	0	1.4	nc	(nc-nc)	Female	15	10.3	145.7	(81.5-240.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	9.1	76.8	(30.8-158.2)	Female	24	22.1	108.4	(69.4-161.3)
Female	9	7.6	119.1	(54.4-226.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	435	386.2	112.6	(102.3-123.7)
Male	7	5.8	119.9	(48.0-247.1)	Female	410	365.0	112.3	(101.7-123.7)
Female	3	2.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	48	55.3	86.8	(64.0-115.1)					
Female	62	52.0	119.3	(91.4-152.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Deerfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	5.7	nc	(nc-nc)	Male	6	3.2	184.6	(67.4-401.9)
Female	6	2.0	305.5	(111.6-665.1)	Female	1	2.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.1	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Female	16	21.2	75.6	(43.2-122.7)	Female	2	2.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.9	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	8.6	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
Female	7	7.7	90.4	(36.2-186.3)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	1.5	nc	(nc-nc)	Male	17	22.9	74.3	(43.3-119.0)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.5	nc	(nc-nc)	Female	2	4.4	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Liver and Intrahepatic Bile Ducts</u>				
Male	1	1.0	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Lung and Bronchus</u>				
Male	3	1.8	nc	(nc-nc)	Male	5	10.7	46.9	(15.1-109.5)
Female	0	1.4	nc	(nc-nc)	Female	6	9.5	63.2	(23.1-137.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dennis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	37	33.6	110.0	(77.5-151.7)	Male	32	15.5	206.8	(141.4-291.9)
Female	20	11.5	174.0	(106.2-268.8)	Female	19	11.4	166.6	(100.2-260.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	4.7	nc	(nc-nc)	Male	4	4.8	nc	(nc-nc)
Female	4	4.0	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	13	14.9	87.3	(46.4-149.3)
Female	105	99.1	106.0	(86.7-128.3)	Female	12	13.9	86.3	(44.5-150.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	3.7	136.7	(44.1-319.0)	Male	13	10.1	128.4	(68.3-219.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	50	48.2	103.8	(77.0-136.8)	Female	16	10.9	146.3	(83.6-237.6)
Female	49	44.7	109.7	(81.2-145.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	9.1	76.8	(30.8-158.3)
Male	8	7.9	100.9	(43.5-198.9)	Female	7	9.8	71.8	(28.8-147.9)
Female	2	2.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	175	122.7	142.6	(122.2-165.4)
Male	2	1.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.3	nc	(nc-nc)	Male	2	8.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	4.8	nc	(nc-nc)
Male	16	12.2	131.4	(75.0-213.4)	<u>Testis</u>				
Female	7	7.8	90.1	(36.1-185.7)	Male	2	1.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	5.0	99.2	(32.0-231.4)	Male	2	2.6	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	8	7.8	102.5	(44.1-202.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	9.2	119.6	(59.6-214.0)	Female	24	21.3	112.9	(72.3-168.0)
Female	8	7.2	110.4	(47.5-217.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	470	409.4	114.8	(104.7-125.7)
Male	6	5.8	103.2	(37.7-224.6)	Female	385	356.2	108.1	(97.5-119.4)
Female	1	2.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	46	61.4	74.9	(54.8-99.9)					
Female	55	54.5	100.9	(76.0-131.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;

- nc = The SIR and 95% CI were not calculated when Obs < 5;

84

Dighton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	6.8	87.8	(32.1-191.1)	Male	0	3.9	nc	(nc-nc)
Female	4	2.4	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.4	nc	(nc-nc)	Male	3	1.0	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	10	3.6	278.5	(133.3-512.2)
Female	32	25.6	125.1	(85.6-176.6)	Female	4	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.2	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	10.3	135.3	(73.9-227.1)	Female	1	2.7	nc	(nc-nc)
Female	8	9.7	82.7	(35.6-162.9)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	3	1.8	nc	(nc-nc)	Male	21	27.3	77.0	(47.6-117.6)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	3.0	nc	(nc-nc)	Female	3	5.3	nc	(nc-nc)
Female	3	1.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	3	1.2	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	4	1.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	1	1.4	nc	(nc-nc)	Male	15	12.8	117.2	(65.5-193.3)
Female	3	0.5	nc	(nc-nc)	Female	15	11.6	128.8	(72.0-212.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

85

Douglas

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	5.2	nc	(nc-nc)	Male	5	3.5	141.4	(45.6-329.9)
Female	0	1.8	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.3	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	28	22.0	127.4	(84.7-184.2)	Female	1	2.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.2	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	8.1	86.2	(34.5-177.5)	Female	1	2.3	nc	(nc-nc)
Female	7	7.3	95.9	(38.4-197.6)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	1.4	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	0	0.6	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	1	2.5	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	<u>Thyroid</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.9	nc	(nc-nc)	Female	5	4.3	116.2	(37.5-271.3)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Male</u>				
Male	1	1.9	nc	(nc-nc)	61	74.1	82.3	(62.9-105.7)	
Female	3	1.5	nc	(nc-nc)	<u>Female</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					68				
Male	0	1.2	nc	(nc-nc)	70.7	96.2	(74.7-122.0)		
Female	0	0.4	nc	(nc-nc)	<u>Lung and Bronchus</u>				
Male	6	9.7	61.9	(22.6-134.7)	<u>Male</u>				
Female	9	8.7	104.0	(47.4-197.4)	61				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

86

Dover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	6.2	nc	(nc-nc)	Male	7	3.6	193.6	(77.6-398.9)
Female	1	1.8	nc	(nc-nc)	Female	6	2.6	226.8	(82.8-493.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.3	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	23	22.4	102.5	(64.9-153.8)	Female	1	2.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	9.5	105.2	(50.4-193.5)	Female	5	2.3	214.2	(69.0-499.9)
Female	8	7.0	114.1	(49.1-224.8)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	1.7	nc	(nc-nc)	Male	43	26.2	164.2	(118.8-221.2)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.8	nc	(nc-nc)	Female	3	4.7	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.1	nc	(nc-nc)	Female	3	4.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>All Sites / Types</u>				
Male	1	2.0	nc	(nc-nc)	Male	92	85.8	107.2	(86.4-131.5)
Female	0	1.4	nc	(nc-nc)					
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	0	1.4	nc	(nc-nc)					
Female	0	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	6	11.9	50.5	(18.4-109.8)					

Female 7 9.3 75.0 (30.1-154.6)

Female 68 70.0 97.2 (75.4-123.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

87

Dracut

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	26.8	119.5	(81.7-168.7)	Male	8	16.0	49.9	(21.5-98.3)
Female	13	9.9	131.8	(70.1-225.4)	Female	15	13.7	109.7	(61.4-181.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	5.7	139.4	(60.0-274.7)	Male	3	4.1	nc	(nc-nc)
Female	3	4.7	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	13	14.5	89.7	(47.7-153.4)
Female	112	107.0	104.7	(86.2-126.0)	Female	18	13.1	137.6	(81.5-217.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	5.1	nc	(nc-nc)	Male	13	10.8	120.2	(64.0-205.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	39	40.7	95.8	(68.1-131.0)	Female	17	11.4	149.6	(87.1-239.5)
Female	48	38.1	125.9	(92.8-167.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	7.7	103.8	(44.7-204.5)
Male	11	7.1	155.8	(77.7-278.9)	Female	9	8.2	109.4	(49.9-207.6)
Female	4	1.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	121	109.1	110.9	(92.1-132.6)
Male	1	2.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	2.1	nc	(nc-nc)	Male	6	6.8	87.6	(32.0-190.8)
<u>Kidney & Renal Pelvis</u>					Female	4	4.0	nc	(nc-nc)
Male	14	12.0	116.5	(63.6-195.5)	<u>Testis</u>				
Female	8	7.5	106.3	(45.8-209.5)	Male	7	4.6	153.7	(61.6-316.7)
<u>Larynx</u>					<u>Thyroid</u>				
Male	7	4.6	151.2	(60.6-311.5)	Male	5	3.7	136.6	(44.0-318.8)
Female	3	1.3	nc	(nc-nc)	Female	12	12.2	98.6	(50.9-172.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	9.0	77.9	(31.2-160.6)	Female	31	22.0	141.2	(95.9-200.4)
Female	6	7.2	83.1	(30.3-180.8)					
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	4	5.8	nc	(nc-nc)					
Female	1	2.0	nc	(nc-nc)					

Lung and Bronchus

Male	63	51.2	123.1	(94.6-157.4)
Female	49	48.6	100.9	(74.6-133.3)

All Sites / Types

Male	386	369.0	104.6	(94.4-115.6)
Female	397	353.6	112.3	(101.5-123.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

88

Dudley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	10.8	55.5	(20.3-120.8)	Male	3	6.1	nc	(nc-nc)
Female	4	3.8	nc	(nc-nc)	Female	9	4.9	182.5	(83.3-346.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.2	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.6	nc	(nc-nc)
Female	34	38.8	87.7	(60.7-122.5)	Female	3	4.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.8	nc	(nc-nc)	Male	6	4.1	145.5	(53.1-316.6)
<u>Colon / Rectum</u>					Female	1	1.9	nc	(nc-nc)
Male	14	16.2	86.4	(47.2-145.0)	<u>Ovary</u>				
Female	15	14.9	100.9	(56.4-166.4)	Female	9	4.2	214.6	(97.9-407.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.8	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.9	nc	(nc-nc)	Male	40	42.1	94.9	(67.8-129.3)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.8	nc	(nc-nc)
Male	5	4.6	109.0	(35.1-254.4)	Female	2	1.6	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.6	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.5	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	4	4.3	nc	(nc-nc)
Male	3	3.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.7	nc	(nc-nc)					
<u>Liver and Intrahepatic Bile Ducts</u>									

Male	1	2.2	nc	(nc-nc)					
Female	0	0.8	nc	(nc-nc)	Female	10	8.0	125.6	(60.2-231.1)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	13	20.1	64.6	(34.3-110.4)	Male	121	144.1	83.9	(69.7-100.3)
Female	12	18.0	66.8	(34.5-116.7)	Female	117	131.1	89.2	(73.8-106.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

89

Dunstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.3	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	11	10.0	110.3	(55.0-197.3)	Female	1	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	3.6	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	4	2.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.7	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	11	10.4	106.2	(52.9-190.0)
Male	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.3	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Leukemia</u>									
Male	0	0.8	nc	(nc-nc)					

Female	0	0.6	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.6	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male	31	34.2	90.8	(61.6-128.8)
Male	4	4.5	nc	(nc-nc)	Female	32	29.8	107.3	(73.4-151.5)
Female	3	3.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

90

Duxbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	15.4	91.0	(49.7-152.7)	Male	23	9.0	255.5	(161.9-383.4)
Female	5	5.7	87.8	(28.3-205.0)	Female	18	7.4	242.8	(143.8-383.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.2	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	6	2.6	231.2	(84.4-503.3)	Female	3	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	9	8.2	110.4	(50.4-209.6)
Female	61	62.0	98.4	(75.3-126.4)	Female	8	7.4	108.1	(46.5-213.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.7	nc	(nc-nc)	Male	3	6.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	2.9	nc	(nc-nc)
Male	24	23.5	102.1	(65.4-151.9)	<u>Ovary</u>				
Female	23	23.0	100.0	(63.4-150.1)	Female	4	6.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	4.1	nc	(nc-nc)	Male	6	4.5	133.2	(48.7-290.0)
Female	1	1.1	nc	(nc-nc)	Female	4	4.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.1	nc	(nc-nc)	Male	100	63.9	156.4	(127.3-190.3)
Female	2	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.9	nc	(nc-nc)
Male	6	6.9	86.5	(31.6-188.2)	Female	2	2.5	nc	(nc-nc)
Female	3	4.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.8	nc	(nc-nc)
Male	1	2.7	nc	(nc-nc)					
Female	2	0.7	nc	(nc-nc)					

Leukemia

Male	12	5.0	240.5	(124.1-420.2)
Female	3	4.2	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	2	3.4	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)

Lung and Bronchus

Male	23	29.0	79.2	(50.2-118.9)
Female	27	26.7	101.3	(66.7-147.4)

Thyroid

Male	5	1.9	258.6	(83.3-603.6)
Female	9	6.3	142.8	(65.2-271.2)

Uteri Corpus and Uterus, NOS

Female	15	12.8	116.9	(65.4-192.9)
--------	----	------	-------	--------------

All Sites / Types

Male	257	211.6	121.5	(107.1-137.3)
Female	226	202.9	111.4	(97.3-126.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

91

East Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	8	11.8	68.0	(29.3-133.9)	Male	8	7.3	110.3	(47.5-217.4)
Female	1	4.3	nc	(nc-nc)	Female	12	6.2	195.0	(100.6-340.6)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	2.6	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.4	nc	(nc-nc)	Male	7	6.5	107.2	(42.9-220.8)
Female	51	48.1	106.0	(78.9-139.4)	Female	7	5.7	122.3	(49.0-252.1)
Cervix Uteri					Oral Cavity & Pharynx				
Female	3	2.3	nc	(nc-nc)	Male	7	5.0	139.7	(56.0-287.9)
Colon / Rectum					Ovary				
Male	16	18.1	88.5	(50.5-143.7)	Female	7	5.1	137.2	(55.0-282.6)
Female	22	16.9	130.5	(81.8-197.6)	Pancreas				
Esophagus					Male	1	3.4	nc	(nc-nc)
Male	1	3.2	nc	(nc-nc)	Female	5	3.6	139.4	(44.9-325.3)
Female	0	0.8	nc	(nc-nc)	Prostate				
Hodgkin Lymphoma					Male	52	48.9	106.4	(79.4-139.5)
Male	1	1.1	nc	(nc-nc)	Stomach				
Female	1	1.0	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Kidney & Renal Pelvis					Female	2	1.8	nc	(nc-nc)
Male	3	5.4	nc	(nc-nc)	Testis				
Female	6	3.3	182.6	(66.7-397.4)					
Larynx									

Male	2	2.1	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	3	0.6	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	2	4.0	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	3	3.2	nc	(nc-nc)	Female	6	5.6	107.0	(39.1-232.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	2.6	nc	(nc-nc)	Female	8	9.9	80.7	(34.8-159.1)
Female	1	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	25	22.5	111.0	(71.8-163.9)	Male	149	165.0	90.3	(76.4-106.0)
Female	13	20.6	63.1	(33.5-107.8)	Female	168	157.0	107.0	(91.4-124.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

92

East Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.4	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	10	8.3	120.5	(57.7-221.6)	Female	1	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
					Female	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	3.7	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.6	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	9.7	72.1	(28.9-148.5)
Female	0	0.1	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	2	1.0	nc	(nc-nc)	Male	4	0.6	nc	(nc-nc)

Female	0	0.6	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male	0	0.3	nc	(nc-nc)
Male	2	0.8	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female	1	1.7	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	0	0.2	nc	(nc-nc)	Male	34	32.6	104.3	(72.2-145.8)
<u>Lung and Bronchus</u>					Female	24	27.6	86.9	(55.6-129.3)
Male	7	4.6	153.3	(61.4-315.8)					
Female	5	3.8	132.6	(42.7-309.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

93

East Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	19.6	102.0	(62.3-157.6)	Male	18	10.2	176.2	(104.4-278.5)
Female	8	7.7	104.0	(44.8-205.0)	Female	6	8.4	71.4	(26.1-155.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.4	147.3	(47.5-343.7)	Male	2	2.9	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	10	9.6	104.5	(50.0-192.2)
Female	80	69.9	114.5	(90.8-142.4)	Female	12	9.5	126.1	(65.1-220.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.9	nc	(nc-nc)	Male	3	6.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	3.5	nc	(nc-nc)
Male	19	28.9	65.8	(39.6-102.7)	<u>Ovary</u>				
Female	28	31.0	90.5	(60.1-130.8)	Female	13	7.6	169.9	(90.4-290.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	4.9	nc	(nc-nc)	Male	4	5.5	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	6	6.6	90.6	(33.1-197.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.2	nc	(nc-nc)	Male	77	74.2	103.8	(81.9-129.7)
Female	2	1.0	nc	(nc-nc)					

Kidney & Renal Pelvis

Male	8	7.8	101.9	(43.9-200.8)
Female	3	5.2	nc	(nc-nc)

Larynx

Male	4	3.1	nc	(nc-nc)
Female	3	0.9	nc	(nc-nc)

Leukemia

Male	3	5.9	nc	(nc-nc)
Female	4	5.3	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	2	3.8	nc	(nc-nc)
Female	4	1.5	nc	(nc-nc)

Lung and Bronchus

Male	21	36.3	57.9	(35.8-88.5)
Female	20	35.1	56.9	(34.8-88.0)

Stomach

Male	7	4.9	142.1	(56.9-292.8)
Female	3	3.4	nc	(nc-nc)

Testis

Male	1	1.9	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	2	2.0	nc	(nc-nc)
Female	3	6.4	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	14	14.3	97.8	(53.4-164.1)
--------	----	------	------	--------------

All Sites / Types

Male	225	251.4	89.5	(78.2-102.0)
Female	246	246.9	99.6	(87.6-112.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

94

Eastham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	11.4	123.1	(67.2-206.6)	Male	12	5.3	225.7	(116.5-394.2)
Female	6	3.4	174.0	(63.5-378.8)	Female	6	3.6	164.5	(60.1-358.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.6	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.1	nc	(nc-nc)
Female	38	31.4	121.1	(85.7-166.2)	Female	3	4.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.2	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
					Female	3	1.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	19	16.4	116.0	(69.8-181.2)	Female	3	3.4	nc	(nc-nc)
Female	17	13.1	130.0	(75.7-208.1)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.7	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	2.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				

Male	1	0.5	nc	(nc-nc)	Male	63	42.0	150.1	(115.3-192.0)
Female	0	0.4	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	2	4.2	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
Female	4	2.4	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	1.7	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	3	3.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	2.0	nc	(nc-nc)	Female	12	6.7	178.4	(92.1-311.7)
Female	0	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	13	21.0	61.9	(32.9-105.8)	Male	161	139.9	115.1	(98.0-134.3)
Female	11	16.8	65.5	(32.6-117.2)	Female	121	109.8	110.2	(91.4-131.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

95

Easthampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	17.8	95.5	(55.6-153.0)	Male	8	10.1	79.6	(34.3-156.8)
Female	4	6.8	nc	(nc-nc)	Female	7	8.6	81.5	(32.6-167.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.4	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	6	2.9	205.5	(75.1-447.4)	Female	3	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	9	9.2	97.5	(44.5-185.0)
Female	70	68.1	102.7	(80.1-129.8)	Female	7	8.8	79.3	(31.8-163.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.1	nc	(nc-nc)	Male	10	6.7	148.7	(71.2-273.5)
Female	1	3.1	nc	(nc-nc)	Female	3	3.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	37	26.6	138.9	(97.8-191.5)	Female	6	7.4	81.5	(29.8-177.3)
Female	29	27.3	106.1	(71.0-152.4)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	4.5	111.3	(35.9-259.8)	Male	6	5.0	119.6	(43.7-260.4)

Female	0	1.3	nc	(nc-nc)	Female	7	5.8	120.3	(48.2-248.0)
Hodgkin Lymphoma					Prostate				
Male	3	1.4	nc	(nc-nc)	Male	58	67.0	86.6	(65.8-112.0)
Female	1	1.2	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	5	4.5	110.2	(35.5-257.2)
Male	9	7.4	121.2	(55.3-230.1)	Female	0	2.9	nc	(nc-nc)
Female	3	4.9	nc	(nc-nc)	Testis				
Larynx					Male	1	2.5	nc	(nc-nc)
Male	4	2.9	nc	(nc-nc)	Thyroid				
Female	1	0.8	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
Leukemia					Female	6	7.2	83.1	(30.4-181.0)
Male	6	5.6	106.9	(39.0-232.6)	Uteri Corpus and Uterus, NOS				
Female	3	4.8	nc	(nc-nc)	Female	7	13.9	50.3	(20.2-103.7)
Liver and Intrahepatic Bile Ducts					All Sites / Types				
Male	4	3.7	nc	(nc-nc)	Male	242	233.2	103.8	(91.1-117.7)
Female	1	1.4	nc	(nc-nc)	Female	202	232.9	86.7	(75.2-99.6)
Lung and Bronchus									
Male	39	32.7	119.2	(84.7-162.9)					
Female	20	32.0	62.4	(38.1-96.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

96

Easton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	23	18.9	121.8	(77.2-182.7)	Male	25	11.9	209.5	(135.5-309.3)
Female	2	6.5	nc	(nc-nc)	Female	8	10.1	79.5	(34.2-156.7)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	4.4	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	3	3.4	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.6	nc	(nc-nc)	Male	15	10.7	140.8	(78.7-232.2)
Female	86	78.3	109.9	(87.9-135.7)	Female	3	9.0	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	9	3.8	235.1	(107.3-446.3)	Male	6	8.4	71.3	(26.0-155.3)
Colon / Rectum					Female	3	3.6	nc	(nc-nc)
Male	29	29.2	99.2	(66.4-142.5)	Ovary				
Female	22	25.7	85.6	(53.6-129.6)	Female	4	8.3	nc	(nc-nc)

Esophagus

Male	7	5.2	135.2	(54.2-278.6)
Female	1	1.3	nc	(nc-nc)

Hodgkin Lymphoma

Male	3	2.0	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)

Kidney & Renal Pelvis

Male	10	8.9	112.6	(53.9-207.1)
Female	2	5.2	nc	(nc-nc)

Larynx

Male	1	3.5	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)

Leukemia

Male	5	6.5	76.5	(24.7-178.6)
Female	6	5.1	118.6	(43.3-258.2)

Liver and Intrahepatic Bile Ducts

Male	3	4.4	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)

Lung and Bronchus

Male	37	36.2	102.3	(72.0-141.0)
Female	33	32.1	102.7	(70.7-144.3)

Pancreas

Male	3	5.6	nc	(nc-nc)
Female	7	5.4	128.6	(51.5-265.0)

Prostate

Male	85	80.6	105.5	(84.3-130.4)
------	----	------	-------	--------------

Stomach

Male	5	4.9	102.5	(33.0-239.2)
Female	1	2.7	nc	(nc-nc)

Testis

Male	3	3.5	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	1	2.8	nc	(nc-nc)
Female	8	9.5	84.4	(36.3-166.3)

Uteri Corpus and Uterus, NOS

Female	17	16.1	105.5	(61.4-169.0)
--------	----	------	-------	--------------

All Sites / Types

Male	276	269.2	102.5	(90.8-115.3)
Female	240	249.9	96.0	(84.3-109.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Edgartown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	4.3	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.9	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
Female	15	15.8	94.7	(53.0-156.3)	Female	2	1.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.7	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.7	nc	(nc-nc)
					<u>Ovary</u>				

Male	3	6.6	nc	(nc-nc)					
Female	10	5.5	182.5	(87.4-335.7)	Female	4	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.2	nc	(nc-nc)	Male	4	1.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	20	18.2	109.9	(67.1-169.8)
Female	1	0.3	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	1	2.0	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	1.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.0	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	8	8.3	97.0	(41.7-191.0)	Male	54	59.9	90.2	(67.7-117.6)
Female	6	7.0	85.6	(31.3-186.4)	Female	58	51.3	113.0	(85.8-146.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

98

Egremont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.4	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	3	7.3	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
					Male	1	0.8	nc	(nc-nc)

Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	3.6	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Female	5	2.6	188.7	(60.8-440.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.7	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	6	9.4	64.0	(23.4-139.4)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.3	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.7	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	14	30.8	45.4	(24.8-76.2)
Male	0	0.5	nc	(nc-nc)	Female	17	24.0	70.9	(41.3-113.5)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	2	4.5	nc	(nc-nc)					
Female	3	3.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

99

Erving

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	1.9	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	5	6.1	81.8	(26.4-190.9)	Female	3	0.8	nc	(nc-nc)

Cervix Uteri

Female	0	0.3	nc	(nc-nc)
--------	---	-----	----	---------

Colon / Rectum

Male	0	2.8	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)

Esophagus

Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)

Hodgkin Lymphoma

Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)

Kidney & Renal Pelvis

Male	0	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)

Larynx

Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)

Leukemia

Male	1	0.6	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)

Lung and Bronchus

Male	3	3.4	nc	(nc-nc)
Female	4	2.8	nc	(nc-nc)

Oral Cavity & Pharynx

Male	0	0.7	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)

Ovary

Female	0	0.7	nc	(nc-nc)
--------	---	-----	----	---------

Pancreas

Male	0	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)

Prostate

Male	5	7.2	69.1	(22.3-161.4)
------	---	-----	------	--------------

Stomach

Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)

Testis

Male	0	0.2	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	3	1.3	nc	(nc-nc)
--------	---	-----	----	---------

All Sites / Types

Male	19	24.4	77.8	(46.8-121.5)
Female	20	20.4	98.0	(59.9-151.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

100

Essex

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	3.8	nc	(nc-nc)	Male	5	2.2	225.1	(72.5-525.2)
Female	0	1.3	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	4	0.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				

Male	0	0.1	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	16	13.6	117.8	(67.3-191.4)	Female	3	1.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.6	nc	(nc-nc)
Male	3	5.8	nc	(nc-nc)	<u>Ovary</u>				
Female	7	4.9	141.6	(56.7-291.7)	Female	0	1.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.0	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	23	15.6	147.0	(93.1-220.6)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.0	nc	(nc-nc)
Male	0	1.7	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.4	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.9	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.8	nc	(nc-nc)	Male	61	52.3	116.7	(89.3-149.9)
Female	0	0.3	nc	(nc-nc)	Female	52	44.7	116.3	(86.9-152.5)
<u>Lung and Bronchus</u>									
Male	5	7.4	67.9	(21.9-158.5)					
Female	11	6.1	180.4	(89.9-322.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

101

Everett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	48	40.1	119.8	(88.4-158.9)	Male	12	22.1	54.4	(28.1-95.0)
Female	10	15.9	63.1	(30.2-116.0)	Female	15	19.6	76.4	(42.7-126.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	16	7.6	210.7	(120.4-342.2)	Male	6	6.0	100.2	(36.6-218.1)

Female	4	6.8	nc	(nc-nc)	Female	1	5.0	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	1.2	nc	(nc-nc)	Male	21	20.4	103.0	(63.7-157.4)
Female	127	152.2	83.5	(69.6-99.3)	Female	27	20.3	133.0	(87.6-193.6)
Cervix Uteri					Oral Cavity & Pharynx				
Female	7	6.9	100.8	(40.4-207.7)	Male	14	14.2	98.7	(53.9-165.6)
Colon / Rectum					Female	9	7.6	118.4	(54.0-224.8)
Male	76	59.2	128.4	(101.1-160.7)	Ovary				
Female	72	62.6	115.0	(89.9-144.8)	Female	22	16.6	132.5	(83.0-200.7)
Esophagus					Pancreas				
Male	15	10.0	150.6	(84.2-248.5)	Male	12	11.2	107.6	(55.5-187.9)
Female	3	3.1	nc	(nc-nc)	Female	22	13.4	163.6	(102.5-247.7)
Hodgkin Lymphoma					Prostate				
Male	3	3.4	nc	(nc-nc)	Male	135	152.2	88.7	(74.4-105.0)
Female	3	3.0	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	15	10.1	147.8	(82.7-243.8)
Male	16	16.3	98.2	(56.1-159.5)	Female	11	6.8	162.7	(81.1-291.2)
Female	20	11.2	178.1	(108.8-275.2)	Testis				
Larynx					Male	5	6.2	80.2	(25.9-187.2)
Male	5	6.4	77.8	(25.1-181.5)	Thyroid				
Female	2	1.9	nc	(nc-nc)	Male	2	4.7	nc	(nc-nc)
Leukemia					Female	19	16.4	116.1	(69.8-181.3)
Male	11	12.7	86.6	(43.2-154.9)	Uteri Corpus and Uterus, NOS				
Female	9	11.2	80.6	(36.8-153.0)	Female	19	31.4	60.5	(36.4-94.4)
Liver and Intrahepatic Bile Ducts					All Sites / Types				
Male	8	7.8	102.2	(44.0-201.4)	Male	548	523.1	104.8	(96.2-113.9)
Female	2	3.2	nc	(nc-nc)	Female	552	530.6	104.0	(95.5-113.1)
Lung and Bronchus									
Male	91	74.2	122.6	(98.7-150.6)					
Female	112	74.4	150.4	(123.9-181.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

102

Fairhaven

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	31	22.4	138.2	(93.9-196.2)	Male	11	11.5	95.3	(47.5-170.5)
Female	7	9.2	76.5	(30.6-157.5)	Female	8	9.8	81.6	(35.1-160.7)

Brain and Other Nervous System

Male	4	3.8	nc	(nc-nc)
Female	4	3.4	nc	(nc-nc)

Breast

Male	0	0.6	nc	(nc-nc)
Female	80	80.5	99.4	(78.8-123.7)

Cervix Uteri

Female	2	3.3	nc	(nc-nc)
--------	---	-----	----	---------

Colon / Rectum

Male	34	32.8	103.5	(71.7-144.6)
Female	28	37.2	75.3	(50.0-108.9)

Esophagus

Male	7	5.5	128.2	(51.3-264.1)
Female	2	1.8	nc	(nc-nc)

Hodgkin Lymphoma

Male	2	1.4	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)

Kidney & Renal Pelvis

Male	15	8.7	171.9	(96.1-283.6)
Female	7	6.1	114.7	(46.0-236.4)

Larynx

Male	3	3.5	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)

Leukemia

Male	8	6.7	119.8	(51.6-236.0)
Female	5	6.2	80.7	(26.0-188.2)

Liver and Intrahepatic Bile Ducts

Male	2	4.2	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)

Lung and Bronchus

Male	39	40.7	95.7	(68.1-130.9)
Female	41	41.2	99.6	(71.4-135.1)

Multiple Myeloma

Male	5	3.3	150.9	(48.6-352.1)
Female	2	2.9	nc	(nc-nc)

Non-Hodgkin Lymphoma

Male	9	10.9	82.9	(37.8-157.4)
Female	10	11.3	88.6	(42.4-163.0)

Oral Cavity & Pharynx

Male	7	7.6	91.9	(36.8-189.3)
Female	3	4.1	nc	(nc-nc)

Ovary

Female	11	8.9	123.5	(61.6-221.0)
--------	----	-----	-------	--------------

Pancreas

Male	1	6.2	nc	(nc-nc)
Female	8	7.9	101.0	(43.5-199.1)

Prostate

Male	104	82.1	126.6	(103.5-153.5)
------	-----	------	-------	---------------

Stomach

Male	6	5.7	106.0	(38.7-230.8)
Female	3	4.1	nc	(nc-nc)

Testis

Male	3	2.3	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	1	2.2	nc	(nc-nc)
Female	4	7.3	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	15	16.6	90.6	(50.7-149.4)
--------	----	------	------	--------------

All Sites / Types

Male	308	282.7	109.0	(97.1-121.8)
Female	268	289.5	92.6	(81.8-104.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Fall River

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				

Male	109	103.5	105.3	(86.5-127.0)	Male	17	54.8	31.0	(18.1-49.7)
Female	49	44.7	109.6	(81.1-144.9)	Female	21	50.1	41.9	(25.9-64.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	19	18.8	101.1	(60.8-157.9)	Male	19	15.4	123.6	(74.4-193.1)
Female	25	17.7	141.1	(91.3-208.3)	Female	13	14.2	91.8	(48.8-157.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	3.0	nc	(nc-nc)	Male	46	51.4	89.5	(65.5-119.4)
Female	328	395.0	83.0	(74.3-92.5)	Female	48	55.9	85.8	(63.3-113.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	25	16.9	147.8	(95.6-218.2)	Male	47	35.6	132.1	(97.0-175.6)
<u>Colon / Rectum</u>					Female	22	20.4	108.1	(67.7-163.6)
Male	174	152.3	114.3	(97.9-132.5)	<u>Ovary</u>				
Female	159	179.9	88.4	(75.2-103.2)	Female	40	43.9	91.1	(65.1-124.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	30	25.3	118.5	(79.9-169.2)	Male	34	28.7	118.5	(82.1-165.6)
Female	8	8.7	91.7	(39.5-180.7)	Female	31	38.5	80.6	(54.7-114.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	10	7.9	126.0	(60.3-231.8)	Male	303	382.3	79.3	(70.6-88.7)
Female	7	7.4	94.2	(37.7-194.0)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	36	26.2	137.4	(96.2-190.2)
Male	42	40.9	102.7	(74.0-138.9)	Female	35	19.8	177.1	(123.4-246.4)
Female	34	30.3	112.4	(77.8-157.0)	<u>Testis</u>				
<u>Larynx</u>					Male	5	13.5	36.9	(11.9-86.1)
Male	26	16.2	160.1	(104.6-234.6)	<u>Thyroid</u>				
Female	12	5.0	238.0	(122.8-415.8)	Male	5	11.0	45.3	(14.6-105.7)
<u>Leukemia</u>					Female	40	39.0	102.7	(73.4-139.8)
Male	39	32.3	120.7	(85.8-164.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	34	31.1	109.2	(75.6-152.7)	Female	73	81.5	89.6	(70.2-112.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	32	19.7	162.6	(111.2-229.6)	Male	1391	1323.8	105.1	(99.6-110.7)
Female	10	8.9	112.1	(53.7-206.1)	Female	1305	1428.6	91.3	(86.5-96.4)
<u>Lung and Bronchus</u>									
Male	268	189.1	141.7	(125.3-159.8)					
Female	177	203.7	86.9	(74.6-100.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	68	56.0	121.4	(94.2-153.9)	Male	47	27.5	171.2	(125.8-227.6)
Female	20	19.9	100.7	(61.5-155.5)	Female	28	21.2	131.8	(87.6-190.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	8.7	115.1	(55.1-211.7)	Male	12	8.2	146.2	(75.5-255.5)
Female	11	7.4	148.6	(74.1-265.8)	Female	9	6.3	143.1	(65.3-271.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.6	nc	(nc-nc)	Male	29	26.0	111.7	(74.8-160.4)
Female	203	180.8	112.3	(97.4-128.8)	Female	27	24.3	111.0	(73.2-161.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	7.1	98.6	(39.5-203.2)	Male	12	18.4	65.4	(33.7-114.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	84	81.5	103.1	(82.2-127.6)	Female	19	19.8	96.2	(57.9-150.2)
Female	59	77.4	76.2	(58.0-98.3)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	10	13.6	73.5	(35.2-135.2)	Male	264	212.0	124.5	(110.0-140.5)
Female	1	3.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	2	2.9	nc	(nc-nc)	Male	9	4.2	214.2	(97.7-406.6)
Female	2	2.5	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	21	21.4	98.0	(60.6-149.8)	Female	37	38.5	96.1	(67.7-132.5)
Female	15	13.7	109.8	(61.4-181.2)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Liver and Intrahepatic Bile Ducts</u>				
Male	14	8.8	159.9	(87.4-268.4)	Male	2	10.3	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	Female	3	3.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Lung and Bronchus</u>				
Male	23	16.0	143.9	(91.2-215.9)	Male	95	103.4	91.8	(74.3-112.3)
Female	20	12.9	154.8	(94.5-239.1)	Female	107	93.7	114.2	(93.6-138.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Fitchburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	41	40.2	102.1	(73.3-138.5)	Male	12	22.0	54.5	(28.1-95.1)
Female	16	16.3	98.2	(56.1-159.4)	Female	12	19.3	62.1	(32.0-108.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	7.8	nc	(nc-nc)	Male	4	6.0	nc	(nc-nc)
Female	8	6.9	116.2	(50.0-228.9)	Female	3	5.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.2	nc	(nc-nc)	Male	22	20.5	107.3	(67.2-162.4)
Female	149	150.3	99.2	(83.9-116.4)	Female	23	20.6	111.6	(70.7-167.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	6.7	90.0	(32.9-195.8)	Male	19	14.3	132.8	(79.9-207.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	56	59.4	94.3	(71.2-122.4)	Female	14	16.6	84.3	(46.1-141.5)
Female	66	65.4	100.8	(78.0-128.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	11.2	80.4	(36.7-152.7)
Male	11	10.0	110.5	(55.1-197.8)	Female	7	14.0	50.0	(20.0-103.1)
Female	4	3.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	141	150.5	93.7	(78.9-110.5)
Male	4	3.5	nc	(nc-nc)	<u>Stomach</u>				
Female	5	3.1	161.2	(51.9-376.1)	Male	9	10.2	88.4	(40.3-167.8)
<u>Kidney & Renal Pelvis</u>					Female	9	7.2	125.1	(57.1-237.5)
Male	16	16.3	98.1	(56.0-159.3)	<u>Testis</u>				
Female	11	11.3	97.7	(48.7-174.8)	Male	11	6.0	183.5	(91.5-328.4)
<u>Larynx</u>					<u>Thyroid</u>				
Male	9	6.4	140.4	(64.1-266.6)	Male	2	4.6	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	15	15.7	95.3	(53.3-157.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	12.9	85.0	(42.4-152.2)	Female	25	30.7	81.4	(52.7-120.1)
Female	7	11.7	59.6	(23.9-122.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	495	522.4	94.8	(86.6-103.5)
Male	10	7.9	126.6	(60.6-232.9)	Female	490	534.3	91.7	(83.8-100.2)
Female	4	3.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	64	73.9	86.5	(66.6-110.5)					
Female	52	74.5	69.8	(52.2-91.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

106
Florida

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	3	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	5	2.6	190.1	(61.3-443.6)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	1.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.1	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	1	0.4	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	1	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.2	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	2	1.5	nc	(nc-nc)	Male	10	11.0	91.1	(43.6-167.5)
Female	2	1.2	nc	(nc-nc)	Female	14	8.7	161.8	(88.4-271.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;

- nc = The SIR and 95% CI were not calculated when Obs < 5;

107

Foxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	16.2	68.0	(33.9-121.7)	Male	19	9.6	197.1	(118.6-307.9)
Female	7	5.9	118.4	(47.4-244.0)	Female	11	8.0	136.9	(68.2-245.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.4	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	1	2.8	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	9	8.7	103.6	(47.3-196.6)
Female	92	64.7	142.2	(114.7-174.4)	Female	7	7.8	90.1	(36.1-185.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.0	nc	(nc-nc)	Male	6	6.7	89.6	(32.7-195.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	32	24.6	129.9	(88.8-183.4)	Female	10	6.9	145.8	(69.8-268.2)
Female	29	22.9	126.5	(84.7-181.6)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	3	4.3	nc	(nc-nc)	Male	69	67.5	102.3	(79.6-129.4)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	2	1.4	nc	(nc-nc)	Male	4	2.4	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	7.3	122.5	(55.9-232.7)	Female	8	13.4	59.5	(25.6-117.3)
Female	3	4.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Male</u>				
Male	1	2.9	nc	(nc-nc)	228	224.3	101.7	(88.9-115.8)	
Female	2	0.8	nc	(nc-nc)	<u>Female</u>				
<u>Leukemia</u>					258				
Male	7	5.3	130.9	(52.4-269.6)	211.9	121.7	(107.3-137.5)		
Female	8	4.3	187.1	(80.6-368.7)	<u>Female</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					258				
Male	2	3.6	nc	(nc-nc)	<u>Female</u>				
Female	1	1.2	nc	(nc-nc)	258				
<u>Lung and Bronchus</u>					<u>Male</u>				
Male	22	31.0	70.9	(44.4-107.3)	<u>Female</u>				
Female	42	28.8	145.9	(105.1-197.2)	258				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

108

Framingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	56	66.9	83.7	(63.2-108.7)	Male	40	38.6	103.5	(74.0-141.0)
Female	27	25.7	105.1	(69.3-153.0)	Female	38	33.6	113.1	(80.0-155.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	13.4	89.9	(46.4-157.0)	Male	12	10.2	117.8	(60.8-205.8)
Female	7	11.4	61.2	(24.5-126.0)	Female	12	8.1	148.1	(76.5-258.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	2.0	nc	(nc-nc)	Male	40	35.2	113.7	(81.2-154.9)
Female	270	258.9	104.3	(92.2-117.5)	Female	34	33.3	102.2	(70.8-142.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	15	12.2	123.4	(69.0-203.5)	Male	29	25.6	113.1	(75.7-162.5)
Female	18	12.7	141.3	(83.7-223.4)	Female	18	12.7	141.3	(83.7-223.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	118	100.3	117.6	(97.4-140.9)	Female	27	28.0	96.3	(63.4-140.1)
Female	117	102.5	114.2	(94.4-136.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	17	19.0	89.6	(52.2-143.5)
Male	13	17.1	75.9	(40.4-129.8)	Female	30	21.8	137.6	(92.8-196.4)
Female	4	5.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	220	262.9	83.7	(73.0-95.5)
Male	9	5.9	152.6	(69.6-289.6)	<u>Stomach</u>				
Female	2	5.1	nc	(nc-nc)	Male	16	17.1	93.6	(53.5-152.0)
<u>Kidney & Renal Pelvis</u>					Female	10	11.1	89.9	(43.0-165.3)
Male	31	28.5	108.7	(73.8-154.3)	<u>Testis</u>				
Female	17	18.5	92.0	(53.5-147.3)	Male	10	11.0	91.3	(43.7-167.9)
<u>Larynx</u>					<u>Thyroid</u>				
Male	8	11.2	71.5	(30.8-141.0)	Male	12	8.5	140.9	(72.7-246.1)
Female	4	3.2	nc	(nc-nc)	Female	35	29.0	120.7	(84.1-167.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	22	21.7	101.5	(63.6-153.7)	Female	62	53.3	116.3	(89.2-149.1)
Female	23	18.6	123.4	(78.2-185.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	845	896.7	94.2	(88.0-100.8)
Male	16	13.9	115.5	(66.0-187.6)	Female	923	884.9	104.3	(97.7-111.3)
Female	6	5.2	114.9	(41.9-250.0)					
<u>Lung and Bronchus</u>									
Male	102	124.7	81.8	(66.7-99.3)					
Female	109	119.7	91.1	(74.8-109.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

109

Franklin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	21.4	98.1	(60.7-150.0)	Male	17	14.1	120.3	(70.1-192.7)
Female	5	7.8	63.9	(20.6-149.2)	Female	15	12.5	120.1	(67.2-198.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	5.4	166.4	(75.9-315.9)	Male	7	3.4	206.6	(82.8-425.7)
Female	3	4.4	nc	(nc-nc)	Female	4	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	7	12.5	55.8	(22.4-115.0)
Female	101	94.0	107.5	(87.5-130.6)	Female	12	10.9	110.2	(56.9-192.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	5.0	nc	(nc-nc)	Male	9	9.4	95.3	(43.5-180.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	31	33.1	93.6	(63.6-132.9)	Female	16	9.9	162.4	(92.8-263.8)
Female	27	30.9	87.3	(57.5-127.0)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	5.8	nc	(nc-nc)	Male	5	6.3	79.8	(25.7-186.3)
Female	3	1.5	nc	(nc-nc)	Female	4	6.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	2	2.4	nc	(nc-nc)	Male	4	5.6	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	9	10.3	87.5	(39.9-166.2)	Male	4	4.7	nc	(nc-nc)
Female	2	6.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.8	nc	(nc-nc)	Female	17	18.6	91.3	(53.2-146.3)
Female	1	1.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>All Sites / Types</u>				
Male	5	7.9	63.4	(20.4-148.0)	Male	302	305.3	98.9	(88.1-110.7)
Female	9	6.4	139.5	(63.7-264.9)					
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	1	5.0	nc	(nc-nc)					
Female	2	1.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	44	40.8	107.9	(78.4-144.8)					

Female 33 38.0 86.8 (59.7-121.8)

Female 307 301.2 101.9 (90.8-114.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;